In the 20th century, we began to die slowly—from our own biology, rather than plagues or predators. Fast deaths are now the exception, not the rule. Today, some 45 million deaths a year owe to biological aging, and we treat these deaths as mostly inevitable. But what if they are not? What if preventing our newly slow deaths is a moral and economic imperative? Drawing on interviews with 102 scientists and original economic modeling, Dr. Romanni-Klein reveals why advancing progress in the young science of agi ...

Core Insights - The iShares Biotechnology ETF provides targeted access to the U.S. biotechnology sector, allowing investors to participate in industry growth and innovation through a liquid investment vehicle [1] - The ETF's strategy focuses on broad exposure to leading biotech companies, balancing established firms with emerging innovators, which aids portfolio managers in specialized healthcare allocation [1] Fund Composition - The fund primarily consists of equity securities from biotechnology firms, with at least 80% of assets in index components and up to 20% in derivatives and cash equivalents [2] - As of January 26, 2026, shares were priced at $175.85, reflecting a 27.4% increase over the past year, with an alpha of 14.48 percentage points compared to the S&P 500 [2] Recent Transactions - Rye Brook Capital LLC sold its entire holding of 24,270 shares in the iShares Biotechnology ETF for an estimated $3.50 million, indicating a significant shift in their biotech sector allocation [3][4] - The position represented 1.8% of Rye Brook Capital's AUM in the previous quarter, and the complete liquidation suggests a fundamental change in investment strategy rather than routine rebalancing [3][4] Market Trends - The biotech sector saw a significant turnaround in 2025, driven by merger and acquisition activities, with major pharmaceutical companies acquiring smaller firms to enhance drug pipelines [5] - The iShares Biotechnology ETF experienced a 28% increase over the last year, but institutional exits during strong performance may indicate profit-taking or skepticism regarding future valuations [5] Investor Suitability - The ETF is suited for risk-tolerant growth investors who believe in the continuation of biotech M&A momentum and can handle the sector's volatility [6] - The fund's market-cap weighting towards established, cash-flow positive biotech companies offers more stability compared to equal-weighted alternatives, providing diversified sector exposure without individual stock risk [6]

Recently, we got an update from Regenxbio Inc. ( RGNX ). Management highlighted 2026 as a make-or-break year for the company, and I’m inclined to agree. If you look at it, there are quite a few near-term regulatory and clinical catalysts thatI hold a Master’s degree in Cell Biology and began my career working for several years as a lab technician in a drug discovery clinic, where I gained extensive hands-on experience in cell culture, assay development, and therapeutic research. That scientific foundation g ...

 Vancouver, British Columbia – TheNewswire - January 27, 2026 – MindBio Therapeutics Corp. (CSE: MBIO; Frankfurt: WF6; OTCQB: MBQIF), (the “Company” or “MindBio”), a biotechnology company that conducts clinical health research and has developed a world first AI prediction tool for drug and alcohol intoxication detection by a simple analysis of the voice, is pleased to announce the Company is targeting the global digital health diagnostics market with a first mover advantage in using speech as a diagnostic ...

Core Insights - Cardiff Oncology, Inc. is undergoing a leadership transition to support its growth and advancement towards late-stage development and key clinical milestones [1][4] - Mani Mohindru, PhD, has been appointed as interim Chief Executive Officer, following the departure of Mark Erlander, PhD, and James Levine [2] - The company is actively searching for a permanent Chief Executive Officer and Chief Financial Officer [3] Leadership Changes - Mani Mohindru has been a member of Cardiff Oncology's Board of Directors since 2021 and has extensive experience in the biotech sector [2][6] - Brigitte Lindsay has been promoted to Chief Accounting Officer, ensuring continuity in the finance function [3] - The leadership transition is aimed at aligning executive and financial leadership with the company's evolving needs [5] Product Development - Cardiff Oncology's lead product candidate, onvansertib, is a specific oral PLK1 inhibitor currently in mid-stage clinical development for RAS-mutated metastatic colorectal cancer (mCRC) [4][7] - Onvansertib is also being evaluated in various other cancers, including pancreatic ductal adenocarcinoma, small cell lung cancer, triple-negative breast cancer, and chronic myelomonocytic leukemia [4] - The company aims to leverage onvansertib's activity to extend its benefits to other solid tumors and hematologic malignancies [5] Strategic Focus - The leadership transition reflects the company's commitment to execution and clinical advancement as its programs mature [4] - Dr. Mohindru emphasizes the importance of sharpening strategic priorities and advancing clinical programs while maintaining a disciplined approach to capital and execution [5]

Core Insights - CRISPR Therapeutics AG is facing renewed pressure due to insider sales, slow revenue growth, and weak product adoption [1] - The company's Momentum score has significantly declined, indicating a drop in investor confidence [2] Revenue Performance - The company's revenue for the third quarter was reported at $890,000, which is substantially below the consensus estimate of $8.06 million [4] - This disappointing revenue performance has contributed to a loss of confidence among investors [4] Insider Activity - CEO Samarth Kulkarni sold over 90,000 shares in a pre-arranged transaction, which has raised concerns among investors despite him retaining approximately 85,000 shares [3] - The timing and scale of these sales have unsettled the market, further impacting the stock's performance [3] Stock Performance - CRISPR Therapeutics AG's stock has dropped over 10% in the past week, leading to a decline in its Momentum score from 76.81 to 50.97 [2] - The stock is currently ranked poorly in Benzinga's Edge Stock Rankings, reflecting unfavorable price trends in both the short and medium terms [4]

Core Insights - The BIOSeedin Winter Innovation Partnering Summit, held on January 11, 2026, in San Francisco, focused on the China Asset Showcase to create a platform for international roadshows and licensing collaborations for Chinese innovative drugs [1] Group 1: Event Overview - The event attracted over 500 industry representatives from more than 10 countries and regions, bringing together multinational companies, leading pharmaceutical firms, biotech companies, and investment institutions across the entire industry chain [2] - Over 300 one-on-one meetings and 18 special roadshows featuring Chinese innovative biotech companies took place, characterized by a dynamic atmosphere of enthusiastic discussions and strong cooperation intentions [2] Group 2: Key Discussions and Presentations - Three cross-border roundtable forums were held, where experienced business development experts and industry leaders discussed oncology, cardio-renal metabolic diseases (CRM), and autoimmune diseases, sharing insights on differentiated therapies for high-incidence cancers and AI-accelerated clinical studies in CRM [3] - The 18 Chinese biotech companies showcased high-quality products in leading areas such as bispecific antibodies, ADCs, and molecular glue, aligning with current industry trends and demonstrating fruitful R&D results in niche areas [3] Group 3: Future Directions - The summit brought together global expertise, activated cross-regional and cross-sector collaboration dynamics, and created a professional bridge for the globalization of innovative drugs from China [4] - BIOSeedin aims to leverage its platform to host high-quality industry events in the future, explore investment opportunities with global partners, and shape the future of biopharmaceutical innovation [4]

Group 1 - Option Therapeutics, a biotechnology company focused on liver diseases, plans to raise up to $25 million through an IPO, offering 2.3 million shares at a price range of $10 to $12 per share [1][2] - The company is a spin-off from BioVie, which has shifted its strategic focus towards neurodegenerative diseases, particularly Alzheimer's and Parkinson's [2] - Option Therapeutics' core product, BIV201, is under evaluation for treating complications related to advanced liver cirrhosis and is currently in patent-pending status in multiple countries [1] Group 2 - The funds raised from the IPO will primarily support the critical Phase 3 clinical trials for BIV201, which has received Fast Track Designation from the FDA [1] - After the IPO, BioVie will retain majority voting power and control over Option Therapeutics, ensuring strategic alignment while allowing independent operations [2] - Option Therapeutics was established in 2025 and plans to list on the NYSE American under the ticker symbol OPTN, with ThinkEquity serving as the sole bookrunner for the transaction [2]

Core Insights - Epidarex Capital has announced the first close of its Fund IV, securing over $145 million in commitments to support the development of therapeutics and medical device companies [1][2]. Investment Strategy - The Fund's initial investors include notable entities such as the British Business Bank, Strathclyde Pension Fund, and the Scottish National Investment Bank, along with various family offices and international investors [2]. - Epidarex aims to invest in high-quality early-stage healthcare innovations based on breakthrough science in the UK and the US, creating new opportunities for researchers and entrepreneurs [2][3]. Focus Areas - The firm targets major unmet disease needs in areas such as oncology, cardiometabolic, autoimmune, and neurological conditions, leveraging research from established and emerging hubs in the UK and US [3]. - Epidarex's strategy involves leading early-stage financings to bridge the equity funding gap and build globally competitive companies [3]. Portfolio and Impact - Epidarex Capital IV is expected to invest in up to 15 companies, focusing on building high-performance leadership teams and guiding companies through critical development milestones [3][4]. - The firm's existing portfolio includes companies like Apellis Pharmaceuticals and Kynos Therapeutics, showcasing its ability to create companies with strategic value and improve health outcomes [4]. Market Outlook - The Managing Partner of Epidarex believes the next three years present a favorable investment window for biotech innovation, emphasizing the importance of funding for standout innovators [4]. - The British Business Bank is committed to increasing investments in UK life sciences, recognizing the sector as a key growth area within the UK Industrial Strategy [4].

Group 1 - The article promotes a weekly newsletter focused on stocks in the biotech, pharma, and healthcare industries, highlighting key trends and catalysts that influence market valuations [1] - The newsletter is led by a biotech consultant with over 5 years of experience and detailed reports on more than 1,000 companies, catering to both novice and experienced investors [1] - The investing group provides insights on product sales forecasts, integrated financial statements, discounted cash flow analysis, and market-specific analyses for major pharmaceutical companies [1]